Bayer-and-Orion-expand-development-program-for-darolutamide-in-prostate-cancer

Phase III study ARANOTE to be initiated in metastatic hormone-sensitive prostate cancer (mHSPC) assessing the novel androgen-receptor antagonist in combination with standard androgen deprivation therapy / Start of patient enrollment expected by the end of Q1 2021 / Study adds to the robust development program for NUBEQA, exploring an opportunity to help even more patients with prostate cancer
Source: Bayer Company News - Category: Pharmaceuticals Source Type: news